You just read:

Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

News provided by

Theravance Biopharma, Inc.

May 20, 2019, 10:15 ET